Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0033377 (
prolapse
)
11,717
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A trial of a mixture of guanethidine 5% and adrenaline 0.5% (
Ganda
5.05) and of guanethidine 3% and adrenaline 0.5% (
Ganda
3.05) was conducted on 90 eyes in 53 patients with open-angle glaucoma or ocular hypertension. The cases fell into 5 groups: untreated cases, cases on pilocarpine 1%, on pilocarpine 2%, on pilocarpine 2 to 4% and adrenaline 1%, and on separate guanethidine 5% and adrenaline 1%. Baseline pressures and average pressures on the previous treatment were established. Substitution with
Ganda
3.05 or 5.05 was started, and the patients attended 2 weeks, 1 month, 3 months, and 6 months from the start of the trial. Applanation tonometry was carried out at the same time of day. The pupil was measured,
ptosis
and superficial punctate corneal staining were looked for and evaluated, and the patients were questioned for symptoms of side effects and acceptability. All the eyes that had previously been treated with pilocarpine 1% or 2% presented significantly lower intraocular pressures on
Ganda
3.05. The patients on pilocarpine 4% and adrenaline 1% also had lower intraocular pressures on
Ganda
5.05, but the significance was less, and the patients on separate guanethidine and adrenaline had a small but not statistically significant drop in pressure.
Ptosis
and discomfort were evaluated on a subjective scale. Patient acceptability was good. The trial was interrupted in 5 cases for various reasons. Tachyphylaxis and tolerance to the mixtures were not observed in this series.
...
PMID:Evaluation of a 5% guanethidine and 0.5% adrenaline mixture (Ganda 5.05) and of a 3% guanethidine and 0.5% adrenaline mixture (Ganda 3.05) in the treatment of open-angle glaucoma. 36 32
A trial of the efficacy of low-concentration nonmiotic therapy was carried out, the aim being to minimise the side effects produced by 1% adrenaline or pilocarpine. A total of 77 eyes with open-angle glaucoma were studied in both parts of the trial. Thirty-nine eyes had a base-line pressure of over 28 mmHg and 28 eyes a pressure of 30 mmHg or over. In the comparison between
Ganda
1.02 and adrenaline 1% (Simplene) the mean lowering of intraocular pressure was 8.6 mmHg with
Ganda
and 7.69 mmHg with Simplene. In the comparison between
Ganda
1.02 and pilocarpine 1% (Sno-Pilo) the mean decrease was 6.34 mmHg with
Ganda
and 6.13 mmHg with Sno-Pilo. The resulting falls in intraocular pressure were highly significant statistically, but the differences between the effects of the 3 drugs were not significant. No significant side effects were reported with
Ganda
1.02, and in particular no
ptosis
or superficial punctate staining of the cornea was noted.
...
PMID:Double-masked cross-over comparison of Ganda 1.02 (guanethidine 1% and adrenaline 0.2% mixture) with gutt. adrenaline 1% (Simplene 1%) and with pilocarpine 1% (Sno-Pilo 1%). 700 78